Literature DB >> 31064037

Clinical Outcome of Patients Over 90 Years of Age Treated for Chronic Subdural Hematoma.

Mauro Dobran1, Alessandra Marini1, Davide Nasi1, Valentina Liverotti1, Roberta Benigni1, Martina Della Costanza1, Fabrizio Mancini1, Massimo Scerrati1.   

Abstract

OBJECTIVE: Chronic subdural hematoma (CSDH) is one of the most common pathology in daily neurosurgical practice and incidence increases with age. The aim of this study was to evaluate the prognostic factors and surgical outcome of CSDH in patients aging over 90 years compared with a control group of patients aging under 90 years.
METHODS: This study reviewed 25 patients with CSDH aged over 90 years of age treated in our department. This group was compared with a younger group of 25 patients aged below their eighties. At admission past medical history was recorded concerning comorbidities (hypertension, dementia, ictus cerebri, diabetes, and heart failure or attack). History of alcohol abuse, anticoagulant and antiplatelet therapy, head trauma and seizures were analyzed. Standard neurological examination and Markwalder score at admission, 48 hours after surgery and 1-6 months follow-up, radiologic data including location and CSDH maximum thickness were also evaluated.
RESULTS: Their mean age was 92.8 years and the median was 92.4 years (range, 90-100 years). In older group, the Markwalder evaluation at one month documented the complete recovery of 24 patients out of 25 without statistical difference with the younger group. This data was confirmed at 6-month follow-up. One patient died from cardiovascular failure 20 days after surgery. The presence of comorbidities, risk factors (antiplatelet therapy, anticoagulant therapy, history of alcohol abuse, and head trauma), preoperative symptoms, mono or bilateral CSDH, maximum thickness of hematoma, surgical time and recurrence were similar and statistically not significant in both groups.
CONCLUSION: In this study, we demonstrate that surgery for very old patients above 90 years of age affected by CSDH is safe and allows complete recovery. Comparing two groups of patients above and under 90 years old we found that complication rate and recovery were similar in both groups.

Entities:  

Keywords:  Complications; Elderly; Hematoma, Subdural, Chronic; Neurosurgical treatment

Year:  2019        PMID: 31064037      PMCID: PMC8752881          DOI: 10.3340/jkns.2018.0011

Source DB:  PubMed          Journal:  J Korean Neurosurg Soc        ISSN: 1225-8245


INTRODUCTION

Chronic subdural hematoma (CSDH) is a collection of blood in the subdural space typically found in elderly and rarely in young population. The incidence of CSDH increases with age : 3.4 per 100000 person-year in people under 60 years of age and 58–80 cases per 100000 person-year in people above 65 years of age [1,3,8,13-15,24]. Surgery is the treatment of choice for CSDH, but in patients over their nineties clinical outcome after surgical treatment is not well investigated. This study evaluates risk factors and clinical outcome of CSDH in very elderly patients treated with surgery.

MATERIALS AND METHODS

This study reviewed 25 patients with CSDH aged over 90 years of age treated in Department of Neurosurgery, Polytechnic University of Ancona, over a period of 5 years, between 2012 and 2016. This group was compared with a control group of 25 patients with an age ranging from 75 to 85 years operated for symptomatic CSDH in the same period. Surgical indications included symptomatic CSDH with radiological signs of space-occupying intradural lesion with midline shift over 1 cm (Fig. 1). All asymptomatic patients aging over 90 years-oldaffected by CSDH were treated conservatively. The only contra-indication for surgery in symptomatic patients was the use of anticoagulant therapy or patients with Alzheimer’s disease or severe dementia.
Fig. 1.

A and B : Pre-operative and post-operative computer tomography scan images depicting bilateral CSDH in a patient aging over 90 years old. CSDH : chronic subdural hematoma.

CSDH radiological diagnosis was obtained by computer tomography (CT) scan. At admission past medical history was recorded concerning comorbidities (hypertension, dementia, ictus cerebri, diabetes, and heart failure or attack). History of alcohol abuse, anticoagulant and antiplatelet therapy, head trauma and seizures were analyzed. Standard neurological examination and Markwalder score [18] at admission was used for clinical evaluation, radiologic data including location and CSDH maximum thickness were also evaluated. Under local anesthesia, a single or double burr hole craniotomy was performed and the hematoma was evacuated by irrigation with physiological saline solution, followed by placement of a subdural closed system drain. The drain was removed 48 hours after surgery and routine CT scan was performed at 48 hours and at 30-day follow-up. Surgical time, use of steroids after surgery and post-operative complications, such as recurrence, were also evaluated. The outcome was assessed with Markwalder score system 48 hours after surgery and at one and sixth months follow-up. The outcome was dichotomized in favorable outcome (Markwalder grade 0–1) and unfavorable outcome (Markwalder grade 2–4) (Table 1).
Table 1.

The Markwalder grading scale

Grade
0Neurologically normal
1Alert and orientated : absence of mild symptoms such as headache, or mild neurological deficit such as reflex asymmetry
2Drowsy or disorientated, or variable neurological deficit such as hemiparesis
3Stuporous, but responding appropriately to noxious stimuli, several focal signs such as hemiplegia
4Comatose with absent motor responses to painful stimuli, decerebrate or decorticate posturing
For comparing of characteristics of both group we used a chi-square test for comparison of non-parametric data. Comparison of quantitative parameters was performed using a ttest. Statistical tests were performed using SPSS software (IBM, Chicago, IL, USA).

RESULTS

Data about 25 super aged patients operated for chronic subdural hematoma were analyzed and described in Table 2. Their mean age was 92.8 years and the median was 92.4 years (range, 90–100). In older group, the Markwalder evaluation at one month documented the complete recovery of 24 patients out of 25 without statistical difference with the younger group. This data was confirmed at 6-month follow-up (Table 3). One patient died from cardiovascular failure 20 days after surgery. In our study the number of elderly patients operated for CSDH increases during recent years (Table 4). The presence of comorbidities, risk factors (antiplatelet therapy, anticoagulant therapy, history of alcohol abuse, and head trauma), pre-operative symptoms, mono or bilateral CSDH, maximum thickness of hematoma, surgical time, and recurrence were similar and statistically not significant in both groups, as reported in Table 5.
Table 2.

Baseline and post-operative characteristics of two groups (super-aged and young control group)

Data analyzedGroup >90 Y.O. (n=25)Group <90 Y.O. (n=25)p-value
Mean age (years)92.480.4<0.0001
Sex0.5
 Male15 (60)17 (68)
 Female10 (40)8 (32)
Comorbility0.11
 Ictus2 (8)2 (8)
 Dementia3 (12)1 (4)
 Heart attack4 (16)2 (8)
 Atrial fibrillation10 (40)4 (16)
 Heart failure2 (8)5 (20)
 None10 (40)7 (28)
Pre-operative risk factors0.33
 Antiplatelet therapy7 (28)7 (28)
 Anticoagulant therapy9 (36)12 (48)
 Hystory of alcohol abuse1 (4)2 (8)
 Head trauma18 (72)9 (36)
Pre-operative symptoms0.2
 Headache21 (84)20 (80)
 Speech disturbance4 (16)10 (16)
 Motor deficit16 (64)15 (60)
 Coma1 (4)2 (8)
 Seizures3 (12)4 (16)
Location of CSDH0.5
 Left5 (20)14 (56)
 Right9 (36)6 (24)
 Bilateral11 (44)5 (20)
Maximum thickness of hematoma (cm)0.5
 <1.57 (28)20 (80)
 1.5–2.29 (36)1 (4)
 >2.29 (36)4 (16)
Surgical time (minnutes)0.5
 <3510 (40)9 (36)
 35–6010 (40)12 (48)
 >605 (20)4 (16)
Corticosteroids in post-operative6 (24)12 (48)0.5
Post-operative complications0.033
 Recurrence5 (20)2 (8)
 Seizure1 (4)0
 One-month death1 (4)00.5

Values are presented as number (%). CSDH : chronic subdural hematoma

Table 3.

The comparison of the Markwalder grading scale between the two groups

Markwalder grading scaleGroup >90 Y.O. (n=25)Group <90 Y.O. (n=25)p-valueOR (95% CI)
Pre-operative0.7390.64 (0.18–2.28)
 Grade 000
 Grade 15 (20)7 (28)
 Grade 213 (52)12 (48)
 Grade 36 (24)3 (12)
 Grade 41 (4)2 (8)
48 hours0.9960.71 (0.15–3.24)
 Grade 012 (48)13 (52)
 Grade 19 (36)9 (36)
 Grade 23 (12)2 (8)
 Grade 301 (4)
 Grade 41 (4)0
One-month0.3530.292 (0.04–2.15)
 Grade 015 (62.5)20 (80)
 Grade 16 (25)4 (16)
 Grade 23 (12.5)1 (4)
 Grade 300
 Grade 400
Six-months0.3530.292 (0.04–2.15)
 Grade 015 (62.5)20 (80)
 Grade 16 (25)4 (16)
 Grade 23 (12.5)1 (4)
 Grade 300
 Grade 400

Values are presented as number (%). OR : odds ratio, CI : confidence interval

Table 4.

The number of case per year in elderly group

Number of case per year in elderly groupValue
20169 (36)
20157 (28)
20144 (16)
20133 (12)
20122 (8)

Values are presented as number (%)

Table 5.

Univariate statistical analysis with chi-square test for pre-operative and post-operative variables affecting the outcome

Data analyzedGroup >90 Y.O.
p-value
Favorable outcome (Markwalder 0–1)Unfavorable outcome (Markwalder 2–4)
Location of CSDH0.902
 Monolateral111
 Bilateral102
Use of antiplatelet or anticoagulant drugs0.986
 Yes92
 No121
Pre-operative markwalder scale0.979
 0–1101
 2–4122
History of trauma0.985
 Yes132
 No81
Surgical time0.999
 <35–60 minutes150
 >60 minutes83
Post-operative complications0.857
 Yes23
 No190

DISCUSSION

Chronic subdural hematoma is one of the most common pathology in daily neurosurgical practice [1,8,13,15,16,20,22-25]. In this study we evaluated the outcome and risk factors in a series of 25 patients operated for CSDH aged over 90 years of age, compared with a younger control group. The outcome in our series was overall favorable. Super-aged patients had a good functional recovery assessed with Markwalder score at 6 months : complete in 20 patients (80%) out of 25, four patients (16%) suffered mild symptoms such as gait impairment or minor disturbance of consciousness (Markwalder grade 1) with a good quality of life. One patient died from cardiovascular failure. These data, compared with the outcome of young people, showed no statistical significance. In literature, complete neurological recovery is documented in 60–90% of operated patients [1,3,4,14,19,24] but mean age is lower than our study’s one. There have been many reports that antiplatelet and anticoagulant therapies are risk factors for CSDH and they increase its incidence [1,7,15,20,21]; in our series 64% of patients were in treatment with anticoagulant and/or antiplatelet drugs. In patients with CSDH using antithrombotic drugs, careful decision- making is compulsory, because these therapies are more common in non-traumatized CSDH patients with cerebrovascular and/or cardiovascular co-morbidities [20]. Furthermore, antiplatelet and anticoagulant drugs may increase the probability of CSDH recurrence as well as the VII factor deficit in young patients [2,8]. Many studies, reported CSDH recurrence rate around 10– 15% [3,8,13,17,25] and elderly patients had higher rate recurrence than younger ones [2,5,6,17]. In our series the recurrence rate in the elderly group was 20%. According to literature, the higher recurrence value in our series may be due to the small superaged patient sample and age selection; this data did not show statistical significance compared to younger patients. It is well established that a head trauma, even mild, is the most common cause of CSDH with a incidence rate of 50– 80% [3]. In the elderly group, history of mild head trauma was documented in 72% of patients, according to literature [2,15]. In our series one patient reported a moderate brain trauma with associated vertebral fracture treated with vertebral stabilization [9-11]. After one month the patient developed CSDH operated with complete recovery. The most frequent presenting symptoms were consciousness disturbance and hemiparesis; in most cases CSDH diagnosis was delayed because neurological symptoms in superaged patients are frequently related to vascular disease or dementia. In our series the hematoma was bilateral in 44% of elderly patients; this data is not comparable with rates between 16 and 20% of other series [14] where the mean age was lower than our study’s one. The high percentage of bilateral hematoma may be related to the frequent brain atrophy of elderly people [13,24,26]. The hematoma thickness was over 2.2 cm in 36% of patients and this may be related to their brain atrophy which let large blood collection in subdural space and delays symptoms recognition [24,26]. The complication rate in the perioperative period was low. Careful pre-operative evaluation of patient’s physical status may be related to this data, meaning that the patient’s general condition represents one of the most important factors postoperative outcomes. The overall mortality rate associated with burr-hole surgery for CSDH in literature ranges between 0.21% to 27.5%; in our study of super-aged patients, mortality rate was 4%, in line with literature [4,12,14,17,19,24,25]. Despite the small sample size of this series, these findings suggest that surgical treatment for CSDH is safe and effective even for patients ageing over 90 years-old.

CONCLUSION

In this study, we demonstrate that surgery for very old patients above 90 years of age affected by CSDH is safe and allows complete recovery; this is obtained when the patient’s physical status is fair and surgical indications and comorbidities are properly analyzed. Comparing two groups of patients above and under 90 years old we found that complication rate and recovery were similar in both groups.
  26 in total

Review 1.  Chronic subdural haematoma in the elderly.

Authors:  V Adhiyaman; M Asghar; K N Ganeshram; B K Bhowmick
Journal:  Postgrad Med J       Date:  2002-02       Impact factor: 2.401

2.  Chronic subdural haematomas and anticoagulation or anti-thrombotic therapy.

Authors:  Tilmann Rust; Nicole Kiemer; Albert Erasmus
Journal:  J Clin Neurosci       Date:  2006-10       Impact factor: 1.961

3.  Chronic subdural hematoma in extremely aged patients.

Authors:  A Spallone; R Giuffrè; F M Gagliardi; R Vagnozzi
Journal:  Eur Neurol       Date:  1989       Impact factor: 1.710

4.  [Chronic subdural haematomas in very elderly patients].

Authors:  Cristina Castro-Rodríguez; Paula Román-Pena; Eduardo Arán-Echabe; Miguel Gelabert-González
Journal:  Rev Esp Geriatr Gerontol       Date:  2016-06-24

5.  Demographics and prevalent risk factors of chronic subdural haematoma: results of a large single-center cohort study.

Authors:  H Baechli; A Nordmann; H C Bucher; O Gratzl
Journal:  Neurosurg Rev       Date:  2004-05-18       Impact factor: 3.042

6.  Chronic subdural hematoma in elderly people: present status on Awaji Island and epidemiological prospect.

Authors:  H Kudo; K Kuwamura; I Izawa; H Sawa; N Tamaki
Journal:  Neurol Med Chir (Tokyo)       Date:  1992-04       Impact factor: 1.742

Review 7.  Natural history of chronic subdural haematoma.

Authors:  K-S Lee
Journal:  Brain Inj       Date:  2004-04       Impact factor: 2.311

8.  Predictors of functional outcomes and recurrence of chronic subdural hematomas.

Authors:  Henri-Arthur Leroy; Rabih Aboukaïs; Nicolas Reyns; Philippe Bourgeois; Julien Labreuche; Alain Duhamel; Jean-Paul Lejeune
Journal:  J Clin Neurosci       Date:  2015-08-08       Impact factor: 1.961

9.  Chronic subdural hematoma in patients over 90 years old in a super-aged society.

Authors:  Sadaharu Tabuchi; Mitsutoshi Kadowaki
Journal:  J Clin Med Res       Date:  2014-07-28

10.  Neurological outcome in a series of 58 patients operated for traumatic thoracolumbar spinal cord injuries.

Authors:  Mauro Dobran; Maurizio Iacoangeli; Lucia Giovanna Maria Di Somma; A Di Rienzo; Roberto Colasanti; Niccolò Nocchi; Lorenzo Alvaro; Elisa Moriconi; Davide Nasi; Massimo Scerrati
Journal:  Surg Neurol Int       Date:  2014-08-28
View more
  1 in total

1.  Surgical Management of Chronic Subdural Hematoma in Older Adults: A Systematic Review.

Authors:  Nathan A Shlobin; Jayanidhi Kedda; Danielle Wishart; Roxanna M Garcia; Gail Rosseau
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-07-13       Impact factor: 6.053

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.